Bayer A G Ord (OP:BAYZF)

52.79 +2.76 (+5.52%)

Delayed Quote Updated: 11:26 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer A G Ord

< Previous 1 2 3 4 5 Next >

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

May 18, 2026

From Bayer

Via Business Wire

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

May 15, 2026

From Bayer

Via Business Wire

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

May 15, 2026

From Bayer

Via Business Wire

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

May 13, 2026

From Bayer

Via Business Wire

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

May 07, 2026

From Bayer

Via Business Wire

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

May 06, 2026

From Bayer

Via Business Wire

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

April 29, 2026

From Bayer

Via Business Wire

New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing

April 29, 2026

From Bayer

Via Business Wire

Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

March 31, 2026

From Bayer

Via Business Wire

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

March 26, 2026

From Bayer

Via Business Wire

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

March 16, 2026

From Bayer

Via Business Wire

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

March 04, 2026

From Bayer

Via Business Wire

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

February 27, 2026

From Bayer

Via Business Wire

Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

February 26, 2026

From Bayer

Via Business Wire

Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

February 23, 2026

From Bayer

Via Business Wire

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

February 12, 2026

From Bayer

Via Business Wire

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

February 05, 2026

From Bayer

Via Business Wire

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

January 29, 2026

From Bayer

Via Business Wire

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

January 27, 2026

From Bayer

Via Business Wire

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

January 20, 2026

From Bayer

Via Business Wire

Bayer Accelerates Pharma Growth on High-Value Portfolio

January 13, 2026

From Bayer

Via Business Wire

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

January 13, 2026

From Bayer

Via Business Wire

Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

January 12, 2026

From Bayer

Via Business Wire

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

January 08, 2026

From Bayer

Via Business Wire

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

January 05, 2026

From Bayer

Via Business Wire

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

December 04, 2025

From Bayer

Via Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

December 03, 2025

From Bayer

Via Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

December 02, 2025

From Bayer

Via Business Wire

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

December 01, 2025

From Bayer

Via Business Wire

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

November 23, 2025

From Bayer

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.